Benoit H. Mulsant, MD, MS

Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; The Royal Hospital, Ottawa, Ontario, Canada

  • 34Articles
  • 178.8KReads
  • 1997–2026Active
  • 118Collaborators
  • 657Citations

About

Benoit H. Mulsant, MD, MS, is affiliated with the Institute of Medical Science and Department of Psychiatry at the University of Toronto, the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health, and The Royal Hospital in Ottawa. With a publication record spanning from 1997 to 2026, Dr. Mulsant has contributed extensively to research on major depressive disorder, schizophrenia and schizoaffective disorders, neurology, electroconvulsive therapy, suicide, anxiety, cognition, and Alzheimer disease. His work includes studies on treatment-resistant depression, the cognitive effects of psychotropic medications, and predictors of treatment outcomes in late-life psychiatric conditions.

Publications

JCP
Concurrent Metformin and Second-Generation Antipsychotics: The Need to Add Vitamin B12
Letter to the Editor

Concurrent Metformin and Second-Generation Antipsychotics: The Need to Add Vitamin B12

March 18, 2026

The authors recommend vigilance for potential B12 deficiency when coprescribing metformin and antipsychotics.
, ,
JCP
Meta-Analysis

Effect of rTMS on Suicidal Ideation in Treatment-Resistant Depression

January 18, 2022

Repetitive magnetic transcranial stimulation (rTMS) has been established as an efficacious treatment for MDD. This meta-analysis looked at its effects on suicidal ideation in depressed patients across the lifespan.
, , , et al
JCP
Original Research

Continuation MST for Treatment-Resistant Depression

October 19, 2021

Magnetic seizure therapy (MST) has shown promise as an alternative to electroconvulsive therapy for acute treatment-resistant depression (TRD). This study examines the efficacy of MST as a continuation treatment...
, , , et al
JCP
Original Research

Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depression

September 29, 2020

This analysis of data from 2 clinical trials examined the effect of benzodiazepines on outcomes in older patients with generalized anxiety disorder or major depressive disorder, including the likelihood...
, , , et al
JCP
Commentary

Dementia in Older Antidepressant-Treated Adults

August 25, 2020

In this commentary, the authors discuss the article by Bartels and colleagues on the relationship between antidepressant use and risk of incident dementia in older adults.
, ,
JCP
Original Research

Predicting Remission in Late-Life Depression

December 10, 2019

Rates of treatment resistance in randomized controlled trials in patients with late-life depression are as high as 77% using SSRIs, yet SSRIs are often used as first-line treatment. This...
, , , et al
JCP
Original Research

Predictors of Extrapyramidal Symptoms With Aripiprazole in Late-Life Depression

June 19, 2018

Augmentation of antidepressants with aripiprazole is effective in treating late-life depression. As an antipsychotic medication, however, aripiprazole potentially leads to extrapyramidal side effects (EPS). Read this article to learn...
, , , et al
JCP
Original Research

Does rTMS Decrease Suicidal Ideation?

April 17, 2018

Read a study on the effects of rTMS on suicidal ideation in patients with treatment-resistant major depression (TRD).
, , , et al
JCP
Original Research

Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression

April 3, 2018

Impaired executive function often accompanies depression in older adults. Can executive dysfunction lead to decreased response to antidepressant treatment? Read this article to learn more about the relationship between...
, , , et al
JCP
Original Research

Anticholinergic Burden and Cognition in Schizophrenia

November 28, 2017

Due to the likelihood of their taking multiple medications, older persons with schizophrenia often have a high anticholinergic burden. Read this article to learn the extent to which high...
, , , et al
JCP
Original Research

Insight Into Schizophrenia in Earlier and Later Life

April 26, 2017

Over half of patients with schizophrenia experience impaired insight into their illness, which often contributes to negative outcomes. Here, increase your own insight into predicting which of your patients...
, , , et al
JCP
Article

Suicidality and Psychotic Depression Treatment Outcome

April 25, 2017

What role does suicidality have on the eventual effect of treatment in patients with psychotic depression? Read this report to explore the interaction of suicidality, randomized treatment assignment of...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe